News | Nuclear Imaging | December 26, 2019

Dr. Thomas Chaly pushes for approval of imaging agent to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s


December 26, 2019 — The Feinstein Institutes for Medical Research has received U.S. Food and Drug Administration (FDA) approval for a new positron emission tomography (PET) drug to combat Parkinson’s disease. Fluorodopa F-18 (FDOPA) Injection (NDA 200655) will help visualize dopaminergic nerve terminals in the striatum for the evaluation of patients with suspected Parkinsonian syndromes.

Thomas Chaly, Ph.D., chief of cyclotron/radiochemistry at the Feinstein Institutes, was instrumental in getting this FDA approval. “This FDA approval is the pinnacle of our venture to have a safe and effective imaging agent for the differential diagnosis of Parkinsonian Syndromes,” said Chaly, who is also an associate investigator in the Institute of Molecular Medicine.

A PET scan is an imaging test that helps to understand the disease condition of the organs at the cellular level. PET uses a short-lived radiopharmaceutical to visually observe the affected area of the organ. In patients with Parkinson’s disease who experience loss of dopaminergic neurons, FDOPA uptake will be lower and this reduced uptake can be visually observed in the PET scan.

Fluorodopa F-18 Injection Helps Visualize Dopaminergic Nerve Terminals

Fluorodopa PET can be used to follow the disease’s progression. In addition, in patients with Parkinson’s disease who have received intracerebral transplantation of adrenal medulla tissue or fetal mesencephalic tissue, FDOPA PET may help to study the integrity and activity of the implant.

“With this approval, PET centers across the United States can incorporate FDOPA F-18 into their diagnostic and treatment follow up programs for patients with Parkinson’s disease,” Chaly said.   

David Eidelberg, M.D., and Vijay Dhawan, Ph.D., helped direct the clinical studies for this NDA approval.

Fluorodopa F-18 Injection is injected into a vein in preparation for a PET scan to help detect the damaged or lost dopaminergic nerve cells. It is to be used in addition to other tests for diagnosing Parkinsonian syndromes. 

To learn more about Fluorodopa F-18 trial. 

 

Related Content:

PET Aids Dopamine Cell Transplantation for Parkinson’s Patients

Trends in Molecular Imaging

Radiopharmaceutical Product Receives Positive Opinion in Europe

Related Content

News | Nuclear Imaging

November 22, 2021 — IBA, a leader in particle accelerator technology, and NorthStar Medical Radioisotopes LLC, a global ...

Time November 22, 2021
arrow
Videos | Radiopharmaceuticals and Tracers

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins ...

Time November 17, 2021
arrow
Videos | Radiation Oncology

Walter Curran, Jr. M.D., FACR, FASCO, GenesisCare global chief medical officer, discusses three technologies that are ...

Time November 16, 2021
arrow
News | Digital Pathology

November 15, 2021 — Saltus Biotech, a leader in 8k image technology, introduces a new high-end computer workstation and ...

Time November 15, 2021
arrow
News | PET Imaging

November 1, 2021 — Researchers in the U.S. and Japan have demonstrated the first experimental cross-sectional medical ...

Time November 01, 2021
arrow
News | Coronavirus (COVID-19)

November 1, 2021 — Long-term cognitive problems after a COVID-19 diagnosis may be a result of fatigue rather than ...

Time November 01, 2021
arrow
News | Molecular Imaging

October 29, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time October 29, 2021
arrow
News | Radiation Oncology

October 20, 2021 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy (BgRT) as a ...

Time October 20, 2021
arrow
News | Radiation Therapy

October 19, 2021 — RAD Technology Medical Systems (RAD) announced that it will be exhibiting at the 2021 American ...

Time October 19, 2021
arrow
News | PET Imaging

October 19, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2021
arrow
Subscribe Now